aTyr Pharma, Inc.
HISTIDYL-TRNA SYNTHETASE-FC CONJUGATES
Last updated:
Abstract:
The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
Status:
Application
Type:
Utility
Filling date:
10 Jun 2021
Issue date:
31 Mar 2022